Mocetinostat

Phase 2Small molecule

MMirati Therapeutics Inc.

Mocetinostat is one of 214 small molecule programs targeting Leiomyosarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

213

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeiomyosarcomaActive, not recruiting

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Urothelial CarcinomaActive, not recruiting

RhabdomyosarcomaActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

LeiomyosarcomaPhase 2

Active, not recruiting

Lung CancerPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 1/Phase 2

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

RhabdomyosarcomaPhase 1

Active, not recruiting

Squamous Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Mocetinostat

MMirati Therapeutics Inc.

Phase 2

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Remeron

OOrganon and Co

Preclinical

1 10

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Rhabdomyosarcoma

NCT04299113

Clinical

Trials by Indication[1]

Urothelial Carcinoma1 trial

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Completed·MMirati Therapeutics Inc.·Phase 2·NCT02236195·17 enrolled

Non-Small Cell Lung Cancer1 trial

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Terminated·MMirati Therapeutics Inc.·Phase 2·NCT02954991·161 enrolled

Lung Cancer1 trial

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03220477·28 enrolled

Rhabdomyosarcoma1 trial

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 1·NCT04299113·38 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02282358·7 enrolled

4 more indications

Squamous Cell Carcinoma1 trial

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Withdrawn·UUniversity Health Network, Toronto·Phase 1·NCT02993991

Patients With Advanced Solid Tumors1 trial

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Terminated·MMirati Therapeutics Inc.·Phase 1/2·NCT02805660·83 enrolled

Leiomyosarcoma1 trial

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT02303262·20 enrolled

MDS1 trial

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Completed·MMirati Therapeutics Inc.·Phase 1/2·NCT02018926·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Mocetinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mocetinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mocetinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mirati Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMirati Therapeutics Inc.

Mocetinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Urothelial Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Lung Cancer1 trial

Rhabdomyosarcoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Squamous Cell Carcinoma1 trial

Patients With Advanced Solid Tumors1 trial

Leiomyosarcoma1 trial

MDS1 trial

References

Drug Info

Quick Facts

Related News